Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsBiotechnology Equipment

PUBLISHER: Grand View Research | PRODUCT CODE: 1433538

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1433538

Asia Pacific Immunohistochemistry Market Size, Share & Trends Analysis Report By Product (Antibodies, Reagents, Equipment, Kits), By Application (Diagnostics, Research), By End-use, By Country, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (5-User License)
USD 5950
Printable PDF (Enterprise License)
USD 7950

Add to Cart

Description

Table of Contents

List of Tables

Asia Pacific Immunohistochemistry Market Growth & Trends:

The Asia Pacific immunohistochemistry market is anticipated to reach USD 837.57 million by 2030 and is projected to grow at a CAGR of 8.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing prevalence of chronic diseases, growing geriatric population, and rising healthcare spending. Moreover, technological advancements in disease diagnosis procedures and techniques are further propelling the growth of the overall Asia Pacific market.

The government and key organizations constantly undertake activities intended to curb cancer-related healthcare expenditure by encouraging patients to undergo regular diagnostic examinations. For instance, in February 2023, Japan International Cooperation Agency (JICA) signed an agreement with the Indian government to extend an ODA loan of above USD 66 million for development of a super-specialty cancer and research center in Mizoram, India. Moreover, in May 2023, Fujitsu conducted a research project in association with Takeda Pharmaceutical Company Limited and the National Cancer Center Japan to analyze the process of recognition, diagnosis, and treatment of ovarian cancer patients. Such favorable initiatives undertaken by government bodies and market players are expected to support the Asia Pacific immunohistochemistry industry growth.

Moreover, aging is associated with a greater risk of infections and autoimmune diseases due to a weakened immune system. According to National Council on Aging's 2023 statistics, an estimated 95% of older people suffer from at least one chronic disease, such as cancer, heart disease, diabetes, or infectious diseases, and 80% suffer from at least two. Incidence of cancer increases 11-fold for people above 65 years of age in comparison with people below 65 years, as per European Society for Medical Oncology. Immunohistochemistry plays a vital role in disease diagnosis and treatment planning. Thus, the rise in the geriatric population is expected to increase the need for immunohistochemistry techniques.

However, the high cost associated with automated immunohistochemistry instruments poses a significant challenge in pathology and biomedical research. These instruments, designed to enhance efficiency and reproducibility, come with substantial upfront expenses. Initial acquisition cost includes instrument, software, and necessary accessories, making it a financial barrier for smaller laboratories. For instance, an advanced immunohistochemistry instrument costs around USD 85,000 to USD 90,000, which poses a high burden on hospitals and diagnostic laboratories in developing economies.

Asia Pacific Immunohistochemistry Market Report Highlights:

  • Based on product, antibodies dominated the product segment with more than 41.5% share in 2023 owing to their significant use in disease diagnosis and research applications
  • Based on application, research application segment is expected to grow at the fastest CAGR over the forecast period
  • In terms of end use, hospitals and diagnostic laboratories segment held the largest share of the Asia Pacific market in 2023. Increase in the number of cancer cases is a significant factor driving the growth of this segment
  • In terms of end use, research institutes segment is expected to grow at the fastest CAGR over the forecast period owing to rising research and development activities
  • Japan dominated the Asia Pacific market owing to factors such as the increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
  • In August 2023, Bio-Rad Laboratories, Inc. launched StarBright Red Dye and expanded its range of antibody markers conjugated to StarBright Dyes which now includes 29 additional cow, dog, human, mouse, and pig targets
Show more
Product Code: GVR-4-68040-180-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Country scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in Asia Pacific
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Country outlook
  • 2.3. Competitive Insights

Chapter 3. Asia Pacific Immunohistochemistry Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increase in prevalence of chronic diseases
      • 3.2.1.2. Growing geriatric population
      • 3.2.1.3. Rise in healthcare spending
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limitations of standardization with IHC techniques
      • 3.2.2.2. High cost of automated IHC instruments
    • 3.2.3. Market challenge analysis
      • 3.2.3.1. Lack of standardization in IHC technique
      • 3.2.3.2. Limited scope for multiple evaluation
  • 3.3. Asia Pacific Immunohistochemistry Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Asia Pacific Immunohistochemistry Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Asia Pacific Immunohistochemistry Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Antibodies
      • 4.4.1.1. Antibodies Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Primary Antibodies
      • 4.4.1.2.1. Primary Antibodies Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Secondary Antibodies
      • 4.4.1.3.1. Secondary Antibodies Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Equipment
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Slide Staining System
      • 4.4.2.2.1. Slide Staining System Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Tissue Microarrays
      • 4.4.2.3.1. Tissue Microarrays Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Tissue Processing Systems
      • 4.4.2.4.1. Tissue Processing Systems Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Slide Scanners
      • 4.4.2.5.1. Slide Scanners Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
      • 4.4.2.6.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Reagents
      • 4.4.3.1. Reagents Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. Histological Stains
      • 4.4.3.2.1. Histological Stains Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. Blocking Sera and Reagents
      • 4.4.3.3.1. Blocking Sera and Reagents Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. Chromogenic Substrates
      • 4.4.3.4.1. Chromogenic Substrates Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.5. Fixation Reagents
      • 4.4.3.5.1. Fixation Reagents Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.6. Organic Solvents
      • 4.4.3.6.1. Organic Solvents Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.7. Proteolytic Enzymes
      • 4.4.3.7.1. Proteolytic Enzymes Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.8. Diluents
      • 4.4.3.8.1. Diluents Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.9. Other Reagents
      • 4.4.3.9.1. Other reagents Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Kits
      • 4.4.4.1. Kits Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Asia Pacific Immunohistochemistry Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Asia Pacific Immunohistochemistry Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Diagnostics
      • 5.4.1.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Cancer
      • 5.4.1.2.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Infectious Diseases
      • 5.4.1.3.1. Infectious Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Cardiovascular Diseases
      • 5.4.1.4.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Autoimmune Diseases
      • 5.4.1.5.1. Autoimmune Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.6. Diabetes Mellitus
      • 5.4.1.6.1. Diabetes Mellitus Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.7. Nephrological Diseases
      • 5.4.1.7.1. Nephrological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.8. Others
      • 5.4.1.8.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Research
      • 5.4.2.1. Research Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Asia Pacific Immunohistochemistry Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Asia Pacific Immunohistochemistry Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals & Diagnostic Laboratories
      • 6.4.1.1. Hospitals & Diagnostic Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Research Institutes
      • 6.4.2.1. Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Asia Pacific Immunohistochemistry Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2023 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. Japan
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework/ reimbursement structure
    • 7.5.3. Competitive scenario
    • 7.5.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. China
    • 7.6.1. Key country dynamics
    • 7.6.2. Regulatory framework/ reimbursement structure
    • 7.6.3. Competitive scenario
    • 7.6.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. India
    • 7.7.1. Key country dynamics
    • 7.7.2. Regulatory framework/ reimbursement structure
    • 7.7.3. Competitive scenario
    • 7.7.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. South Korea
    • 7.8.1. Key country dynamics
    • 7.8.2. Regulatory framework/ reimbursement structure
    • 7.8.3. Competitive scenario
    • 7.8.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Australia
    • 7.9.1. Key country dynamics
    • 7.9.2. Regulatory framework/ reimbursement structure
    • 7.9.3. Competitive scenario
    • 7.9.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Singapore
    • 7.10.1. Key country dynamics
    • 7.10.2. Regulatory framework/ reimbursement structure
    • 7.10.3. Competitive scenario
    • 7.10.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.11. Thailand
    • 7.11.1. Key country dynamics
    • 7.11.2. Regulatory framework/ reimbursement structure
    • 7.11.3. Competitive scenario
    • 7.11.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.12. Malaysia
    • 7.12.1. Key country dynamics
    • 7.12.2. Regulatory framework/ reimbursement structure
    • 7.12.3. Competitive scenario
    • 7.12.4. Malaysia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.13. Indonesia
    • 7.13.1. Key country dynamics
    • 7.13.2. Regulatory framework/ reimbursement structure
    • 7.13.3. Competitive scenario
    • 7.13.4. Indonesia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.14. Philippines
    • 7.14.1. Key country dynamics
    • 7.14.2. Regulatory framework/ reimbursement structure
    • 7.14.3. Competitive scenario
    • 7.14.4. Philippines market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.15. Vietnam
    • 7.15.1. Key country dynamics
    • 7.15.2. Regulatory framework/ reimbursement structure
    • 7.15.3. Competitive scenario
    • 7.15.4. Vietnam market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Thermo Fisher Scientific Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck KGaA
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Danaher Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. PerkinElmer, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bio-Rad Laboratories, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Cell Signaling Technology, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bio SB
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Agilent Technologies, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abcam plc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. HiMedia Laboratories
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. IMGENEX INDIA Pvt. Ltd.
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Sino Biological, Inc.
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives
    • 8.3.17. NICHIREI BIOSCIENCES INC. (NICHIREI CORPORATION)
      • 8.3.17.1. Company overview
      • 8.3.17.2. Financial performance
      • 8.3.17.3. Product benchmarking
      • 8.3.17.4. Strategic initiatives
    • 8.3.18. MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
      • 8.3.18.1. Company overview
      • 8.3.18.2. Financial performance
      • 8.3.18.3. Product benchmarking
      • 8.3.18.4. Strategic initiatives
    • 8.3.19. Immuno-Biological Laboratories Co,Ltd.
      • 8.3.19.1. Company overview
      • 8.3.19.2. Financial performance
      • 8.3.19.3. Product benchmarking
      • 8.3.19.4. Strategic initiatives
    • 8.3.20. Kyowa Kirin Co., Ltd.
      • 8.3.20.1. Company overview
      • 8.3.20.2. Financial performance
      • 8.3.20.3. Product benchmarking
      • 8.3.20.4. Strategic initiatives
    • 8.3.21. Amos Scientific PTY. LTD.
      • 8.3.21.1. Company overview
      • 8.3.21.2. Financial performance
      • 8.3.21.3. Product benchmarking
      • 8.3.21.4. Strategic initiatives
    • 8.3.22. PathnSitu Biotechnologies Pvt Ltd
      • 8.3.22.1. Company overview
      • 8.3.22.2. Financial performance
      • 8.3.22.3. Product benchmarking
      • 8.3.22.4. Strategic initiatives
    • 8.3.23. PathnSitu Biotechnologies Pvt Ltd
      • 8.3.23.1. Company overview
      • 8.3.23.2. Financial performance
      • 8.3.23.3. Product benchmarking
      • 8.3.23.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-180-6

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Asia Pacific immunohistochemistry market, by country, 2018 - 2030 (USD Million)
  • Table 3 Asia Pacific immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 4 Asia Pacific immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 5 Asia Pacific immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 6 Japan immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 7 Japan immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 8 Japan immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 9 China immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 10 China immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 11 China immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 12 India immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 13 India immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 14 India immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 15 South Korea immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 16 South Korea immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 17 South Korea immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Australia immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 19 Australia immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 20 Australia immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 21 Thailand immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 23 Thailand immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Singapore immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 25 Singapore immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 26 Singapore immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 27 Malaysia immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 28 Malaysia immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 29 Malaysia immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Indonesia immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 31 Indonesia immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 32 Indonesia immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Philippines immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 34 Philippines immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 35 Philippines immunohistochemistry market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Vietnam immunohistochemistry market, by product, 2018 - 2030 (USD Million)
  • Table 37 Vietnam immunohistochemistry market, by application, 2018 - 2030 (USD Million)
  • Table 38 Vietnam immunohistochemistry market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in APAC
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Asia Pacific immunohistochemistry market: market outlook
  • Fig. 10 Asia Pacific immunohistochemistry competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Asia Pacific immunohistochemistry market driver impact
  • Fig. 16 Asia Pacific immunohistochemistry market restraint impact
  • Fig. 17 Asia Pacific immunohistochemistry market strategic initiatives analysis
  • Fig. 18 Asia Pacific immunohistochemistry market: Product movement analysis
  • Fig. 19 Asia Pacific immunohistochemistry market: Product outlook and key takeaways
  • Fig. 20 Antibodies market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 21 Primary antibodies estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 22 Secondary antibodies market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 23 Equipment estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 24 Slide staining system market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 25 Tissue microarrays market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 26 Tissue processing systems market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 27 Slide scanners market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 28 Others estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 29 Reagents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 30 Histological stains market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 31 Blocking sera and reagents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 32 Chromogenic substrates market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 33 Fixation reagents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 34 Organic solvents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 35 Proteolytic enzymes market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 36 Diluents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 37 Other reagents market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 38 Kits estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • Fig. 39 Asia Pacific immunohistochemistry Market: Application movement Analysis
  • Fig. 40 Asia Pacific immunohistochemistry market: Application outlook and key takeaways
  • Fig. 41 Diagnostics market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 42 Cancer market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 43 Infectious diseases market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 44 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 45 Autoimmune diseases market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 46 Diabetes mellitus market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 47 Nephrological diseases market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 48 Others market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 49 Research market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 50 Asia Pacific immunohistochemistry market: End use movement analysis
  • Fig. 51 Asia Pacific immunohistochemistry market: End use outlook and key takeaways
  • Fig. 52 Hospitals and diagnostic laboratories market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 53 Research institutes market estimates and forecasts,2018 - 2030 (Revenue, USD Million)
  • Fig. 54 Others market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 55 Asia Pacific immunohistochemistry market: Country outlook and key takeaways
  • Fig. 56 Japan key country dynamics
  • Fig. 57 Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 58 China key country dynamics
  • Fig. 59 China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 60 India key country dynamics
  • Fig. 61 India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 62 South Korea key country dynamics
  • Fig. 63 South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 64 Australia key country dynamics
  • Fig. 65 Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 66 Singapore key country dynamics
  • Fig. 67 Singapore market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 70 Malaysia key country dynamics
  • Fig. 71 Malaysia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 72 Indonesia key country dynamics
  • Fig. 73 Indonesia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 74 Philippines key country dynamics
  • Fig. 75 Philippines market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 76 Vietnam key country dynamics
  • Fig. 77 Vietnam market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 78 Market share of key market players - Asia Pacific immunohistochemistry market, 2023
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!